Results: In total, 67 patients (45 CD, 22 UC) were analysed. Median treatment duration was 78 weeks . Drug survival was comparable between CD and UC patients (p = 0.180). Twenty out of 67 patients (16 CD, 4 UC) discontinued vedolizumab treatment of which 90% within the first year. Reasons for discontinuation were lack of response (n = 15; 13 CD, 2 UC), extra-intestinal manifestations (n = 2), patient wish (n = 1), anaphylactic reaction (n = 1) and death (n = 1, unrelated to vedolizumab). Clinical activity scores could be compared with baseline in 68.9% and 64.4% of CD patients and 54.5% and 50.0% of UC patients at 6 and 12 months respectively. Clinical response and remission rates were 48.3% and 32.3% at 6 months, and 41.4% and 31.0% at 12 months in CD patients and clinical response and remission rates were 66.7% and 41.7% at 6 months, and 50.0% and 33.3% at 12 months in UC patients. Baseline and follow-up endoscopy were available in 26/67 (38.8%) patients (15 CD, 11 UC), with a median time to endoscopy of 40 weeks (IQR 27-64). Endoscopic response was seen in 8/15 (47%) CD patients, and 1/15 (7%) CD patients was in endoscopic remission. Endoscopic response was seen in in 9/11 (81.8%) UC patients, and 5/11 (45.5%) UC patients were in endoscopic remission.
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Complications related to varicella zoster virus infection in patients with inflammatory bowel disease in the pre-JAK inhibitors era: A prospective study R 
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
Background: Retrospective studies performed with databases have shown that herpes zoster infection (HZ) is more frequent in patients with inflammatory bowel disease (IBD) than in the general population. To know the risk of this infection and its complications is important, especially before the introduction of JAK inhibitors into the therapeutic arsenal for IBD patients. Our aim is to know the seroprevalence of varicella zoster virus (VZV) infection, and prospectively evaluate the complications associated to this infection (varicella and HZ) in adults with IBD. Methods: Prospective and single centre study in IBD patients attended at an IBD Unit between 2007 and 2017. Seroprevalence of VZV infection was assessed using IgG serological assays. Varicella cases are described. Incidence and risk factors for HZ were analysed. Results: 96.1% of 1737 IBD patients were VZV IgG positive (seroprevalence). Among 68 seronegative patients, 32 could have been vaccinated. During follow-up 9 subjects presented a varicella (7 under immunosuppressive and / or biological treatment) and 4 of them required hospitalisation. There were no deaths associated with this acute infection. After 10,805 patient-years of follow-up, 110 cases of HZ were diagnosed; the incidence of HZ was 1.02 cases/100 patient-years (95% CI, 0.83/100 patient-years-1.21/100 patient-years). Risk factors for HZ were age (p .008), diagnosis of Background: Low vaccination rates against hepatitis B virus(HBV) and sub-optimal response to vaccination are reported in patients with IBD. We initiated a multi-centre study in the metropolitan area of Athens, to assess: a)the percentage of IBD patients with protective anti-HBs levels and b)the response to vaccination. Methods: We reviewed the clinical records of all IBD patients with regular follow-up at 4 tertiary hospitals in Athens. All patients were tested for HBsAg, anti-HBs and anti-HBc antibodies. Patients with negative tests for both HBsAg and anti-HBc were managed as follows: a)negative anti-HBs without history of vaccination: 3-dose vaccination(0,1,6mo) with 20μg b)history of vaccination: anti-HBs levels >100 IU/l: annual follow-up of anti-HBs levels; anti-HBs 10-100 IU/l, 1-3 20μg doses with anti-HBs measurement after each dose; undetectable anti-HBs, 1-3 20μg doses with anti-HBs measurement after each dose. Vaccination was considered complete when anti-HBs>100 IU/l were detected. In patients with negative anti-HBs levels after 3x20μg doses, vaccination was repeated with a double dose(40μg) with anti-HBs measurement after each dose. Results: Our study population consists of 686 IBD patients. Among those, 575 patients had recent HBV serology(84%). In our cohort we identified 8 cases of chronic HBV infection(HBsAg+) and 38 patients with previous exposure to HBV (HBsAg-, anti-HBc+) . Protective immunity due to previous vaccination(HBsAg-, antiHBc-, anti-HBs+>100 iu/l) was detected in 24%(n = 140). Suboptimal anti-HBs levels were seen in 12%(n = 70). The majority of patients were negative for all three markers, indicating lack of effective vaccination(n = 319, 56%). Vaccination has been commenced in 243 patients. 206 patients completed their regimens. Response has been assessed in 177 patients: 106(60%) demonstrated sufficient response while 71 failed to develop immunity to HBV. Among nonresponders, 39 received repeat vaccination, with 22 having achieved protective anti-HBs levels and 17 failing to respond again. There was a significant correlation between "low-tier"(only 5-ASA or no treatment) therapy at time of vaccination and successful response (p = 0.015). There was also strong association (p < 0.001) between age and presence of protective immunity, probably due to the application of HBV vaccination in the last 2 decades in Greece. Conclusions: A significant percentage of Greek IBD patients lack protective immunity against HBV. Classical vaccination regimen often fails to induce adequate levels of anti-HBs antibodies especially in cases that are receiving "high-tier" treatment (immunomodulation and/or immunosuppression). Increased awareness, intensified vaccination protocols and frequent testing of response may be required in this population.
